Chemotherapy after kidney cancer surgery could halve the risk of relapse

Written by Heather Jones, Future Science Group

Researchers at The Institute of Cancer Research (London, UK) and the Lancashire Teaching Hospitals NHS Foundation Trust (Preston, UK) have revealed that patients with a rare form of kidney cancer who are treated with combination chemotherapy after surgery have a reduced risk of their cancer coming back or spreading. In addition, the patients were more likely to live cancer free for 3 years or more. The results of the study, published in The Lancet, could change clinical practice around the world. Cancer of the ureter and renal pelvis is relatively rare form of kidney cancer, with approximately 1000 individuals being...

To view the full article, please register now for access

It's completely free